Pharma Contract Manufacturers

Kopran soars 10%, rallies 154% in FY27 so far; what's driving pharma stock?

Kopran share price: Average volumes on the counter more than doubled with a combined 13.12 million shares having changed hands on BSE and NSE.

Morepen Labs zooms 112% in 6 weeks; stock hits multi-year high; here's why

Morepen Laboratories' share price hit a multi-year high of ₹112.85, soaring 8 per cent on the BSE in Wednesday's intra-day trade.

Sai Life Science surges 8% in two days; stock hits new high in weak market

In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex.

Pharma shares shine: Divi's, Laurus hit new highs; zoom up to 91% in FY27

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Laurus Labs extends rally, up 97% from Feb low; tops Dr Reddy's market-cap

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

Laurus Labs rallies 4%, up 55% in 5 months; brokerages see more upside

The stock price of Laurus Labs hit a new high of ₹1,662.45 in intra-day deals on Monday; the stock has zoomed 176% in the past 14 months from levels of ₹601.75 on May 27, 2025.

Aether Industries zooms 75% so far in 2026; should investors book profit?

Share price of Aether Industries hit a new high of ₹1,507.20, soaring 7% on the BSE in Thursday's intra-day trade.

Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

Supriya Lifescience up 15% on healthy Q4 results; should you buy or hold?

The company's management said improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the financial year 2025-26.

CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week

The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.

Acutaas Chemicals zooms 50% in 2 months, hits new high; here's why

In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.

Laurus Labs jumps 4% on huge volumes; Motilal projects 30% further upside

Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Laurus Labs soars 8% in 2 days, nears record high; analysts see more upside

The management expects better Q4 and a decent overall growth in FY27

Sai Life rallies 5%, hits all-time high; what's driving pharma stock?

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.